Personalis (PSNL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for May 16, 2025, to be held virtually, with record date set as March 20, 2025.
Three main proposals: election of two Class III directors, ratification of BDO USA, P.C. as auditor, and advisory approval of executive compensation.
Board recommends voting in favor of all proposals; quorum requires majority of outstanding shares.
Stockholders can vote online, by phone, or by mail, and may submit questions in advance or during the meeting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors (A. Blaine Bowman and Karin Eastham) to serve until 2028.
Proposal 2: Ratify BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2025.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Board recommends voting “For” all proposals; director nominations for 2026 due by December 4, 2025.
Board of directors and corporate governance
Board consists of seven directors, majority independent, with separate Chair and CEO roles.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
Annual board and committee self-assessments; directors expected to attend meetings and pursue continuing education.
Non-employee directors compensated with cash retainers and stock options; policy updated in February 2024.
Latest events from Personalis
- Clinical test volume soared nearly 400% in 2025, with 2026 revenue guided to $78–$80 million.PSNL
Q4 202527 Feb 2026 - Ultra-sensitive ctDNA testing detects cancer recurrence and therapy response earlier than current methods.PSNL
Status Update3 Feb 2026 - Q2 revenue up 35% year-over-year, guidance raised, net loss narrowed, but risks remain.PSNL
Q2 20242 Feb 2026 - Q3 revenue up 41% year-over-year, biopharma surges, and cash runway extends to 2027.PSNL
Q3 202416 Jan 2026 - 14M shares from a $50M private placement registered for resale; no proceeds to the company.PSNL
Registration Filing16 Dec 2025 - 3.5M shares registered for resale after $17.7M private placement with Tempus AI, Inc.PSNL
Registration Filing16 Dec 2025 - 2024 revenue up 15% to $84.6M; net loss narrows; partnerships and MRD drive outlook.PSNL
Q4 20241 Dec 2025 - Board recommends director elections, auditor ratification, and say-on-pay at virtual meeting.PSNL
Proxy Filing1 Dec 2025 - Clinical test volumes surged, but biopharma delays and risks drove lower revenue and guidance.PSNL
Q2 202523 Nov 2025